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Background. Glioblastoma (GBM) is a highly aggressive type of glioma with poor prognosis. However, a small number of patients live
much longer than the median survival. A better understanding of these long-term survivors (LTSs) may provide important insight into
the biology of GBM.
Methods. We identified 7 patients with GBM, treated at Memorial Sloan-Kettering Cancer Center (MSKCC), with survival .48 months.
We characterized the transcriptome of each patient and determined rates of MGMT promoter methylation and IDH1 and IDH2 muta-
tional status. We identified LTSs in 2 independent cohorts (The Cancer Genome Atlas [TCGA] and NCI Repository for Molecular Brain
Neoplasia Data [REMBRANDT]) and analyzed the transcriptomal characteristics of these LTSs.
Results. The median overall survival of our cohort was 62.5 months. LTSs were distributed between the proneural (n¼ 2), neural
(n¼ 2), classical (n¼ 2), and mesenchymal (n¼ 1) subtypes. Similarly, LTS in the TCGA and REMBRANDT cohorts demonstrated diverse
transcriptomal subclassification identities. The majority of the MSKCC LTSs (71%) were found to have methylation of the MGMT
promoter. None of the patients had an IDH1 or IDH2 mutation, and IDH mutation occurred in a minority of the TCGA LTSs as well.
A set of 60 genes was found to be differentially expressed in the MSKCC and TCGA LTSs.
Conclusions. While IDH mutant proneural tumors impart a better prognosis in the short-term, survival beyond 4 years does not require
IDH mutation and is not dictated by a single transcriptional subclass. In contrast, MGMT methylation continues to have strong prog-
nostic value for survival beyond 4 years. These findings have substantial impact for understanding GBM biology and progression.
Keywords: gene expression, glioblastoma, prognostic genes, TCGA.
Glioblastomas (GBMs) are the most common primary brain tumor
in adults.1 Despite advances in therapy over the past few dec-
ades, prognosis remains poor with a median survival of 12–15
months.2 Long-term survivors (LTSs) of this disease exist but are
rare, and the factors that predict prolonged survival are still
incompletely defined.
Historically, prognostic factors consisted of clinical variables in-
cluding age, performance status, and extent of resection.3 More
recently, methylation of the MGMT promoter has been identified
as a favorable prognostic factor, particularly in patients treated
with concomitant and adjuvant temozolomide (TMZ).4 – 6 Further-
more, recent studies have demonstrated the prognostic signifi-
cance of mutations in IDH1 and IDH2.7 – 10 Mutations in IDH1
and 2 occur frequently in intermediate-grade gliomas and sec-
ondary glioblastomas and are associated with better prognosis
than IDH wild-type gliomas. The presence of IDH mutation
imparts the glioma hypermethylator phenotype (G-CIMP).9
With the advent of large-scale gene expression studies of GBM,
the disease has been classified into molecular subtypes.11,12 The
Cancer Genome Atlas (TCGA) project identified 4 distinct sub-
groups: proneural, neural, classical, and mesenchymal.11,13
Though other gene expression profiling studies have found an as-
sociation between subtype and prognosis,12,14 the TCGA failed to
show a correlation between subtype and survival with the excep-
tion of the finding that IDH-mutant/G-CIMP tumors were asso-
ciated with better survival.7,11,13
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In this study, we sought to identify the molecular characteris-
tics of GBM patients who survived at least 48 months. Forty-eight
months represents extreme long-term survival in this disease
with a median survival of 12–15 months. Unlike other studies,
we focused on very LTSs with a median survival in our cohort of
more than 5 years. Importantly, it is not yet known what the tran-
scriptomal subclass characteristics of such GBM LTSs are and how
known prognostic factors such as MGMT relate to transcriptomal
identity in these LTS patients. We identified 7 patients with GBM
treated at Memorial Sloan-Kettering Cancer Center (MSKCC)
with survival.48 months. We examined MGMT promoter methy-
lation and IDH1 and IDH2 mutation status in our LTS cohort. We
characterized the transcriptomes of each patient and correlated
gene expression data from our patients with the data from the
TCGA and NCI Repository for Molecular Brain Neoplasia Data
(REMBRANDT). We used the data from the TCGA and LTSs at our
institution to identify genes prognostic of survival and validated
these genes using an independent dataset.
Materials and Methods
Clinical Characteristics
Clinical and survival data for the MSKCC LTSs were obtained by
retrospective review of patients’ charts. Patients’ age, sex, treat-
ment, extent of resection, Karnofsky performance status (KPS),
and survival were determined. Overall survival (OS) was calcu-
lated using the Kaplan-Meier method. The 7 patients represented
consecutive patients at MSKCC who met the survival criteria. All
patients were consented and approved by the institutional review
board for inclusion in this study.
Tumors
All tumors (n¼ 7) were obtained following surgical resection at
MSKCC as part of routine clinical care and snap-frozen. Tumors
were obtained in accordance with institutional review board pol-
icies at MSKCC. Each sample was examined histologically by 3 in-
dependent neuropathologists and confirmed to be World Health
Organization (WHO) grade IV glioma (GBM). Before analysis,
tumors were sectioned and microdissected. Genomic DNA or
RNA was extracted using the DNeasy kit (Qiagen) or RNeasy
Lipid Tissue Mini Kit (Qiagen) according to the manufacturers’
instructions. Nucleic acid quality was determined using the
Agilent 2100 Bioanalyzer.
IDH1 and IDH2 Mutation Analysis
Sanger sequencing was performed to identify mutations in R132
of IDH1 and R172 of IDH2, as previously described.9 The exons of
these residues were sequenced. Standard M13 tails were added
to the tails to facilitate Sanger sequencing. PCR reactions were
carried out in 384-well plates in a Duncan DT-24 water bath ther-
mal cycler with 10 ng of whole genome-amplified DNA (REPLI-g
Midi, Qiagen) as a template, using a touchdown PCR protocol with
KAPA Fast HotStart (Kapa Biosystems). The touchdown PCR
method consisted of: 1 cycle of 958C for 5 minutes; 3 cycles of
958C for 30 seconds, 648C for 15 seconds, 728C for 30 seconds;
3 cycles of 958C for 30 seconds, 628C for 15 seconds, 728C for
30 seconds; 3 cycles of 958C for 30 seconds, 608C for 15 seconds,
728C for 30 seconds; 37 cycles of 958C for 30 seconds, 588C for 15
seconds, 728C for 30 seconds; and 1 cycle of 708C for 5 minutes.
Templates were purified using AMPure (Agencourt Biosciences).
The purified PCR reactions were split in two and sequenced bidir-
ectionally with M13 forward and reverse primer and the Big Dye
Terminator Kit v.3.1 (Applied Biosystems) at Agencourt Bios-
ciences. Dye terminators were removed using the CleanSEQ kit
(Agencourt Biosciences), and sequence reactions were run on
ABI PRISM 3730xl sequencing apparatus (Applied Biosystems).
Passing reads were assembled against reference sequences con-
taining all coding exons, including 5 kb upstream and down-
stream of the gene, using command line Consed 16.0. Geneious
R7 (version 7.0.4) was used to check for the presence or absence
of point mutations at R132 in IDH1 and R172 in IDH 2.7,9,10,13
Analysis of MGMT Promoter Methylation
Extracted DNA was subjected to bisulphite modification using the
EZ DNA Methylation Kit (Zymo Research) according to the manu-
facturer’s instructions. Primer sequences of MGMT were for the
unmethylated reaction 5′-TTTGTGTTTTGATGTTTGTAGGTTTTTGT-3′
(forward primer) and 5′-AACTCCACACTCTTCCAAAAACAAAACA-3′
(reverse primer) and for the methylated reaction 5′-TTTCG
ACGTTCGTAGGTTTTCGC-3′ (forward primer) and 5′-GCACTCTT
CCGAAAACGAAACG-3′ (reverse primer), as have been previously
described.6 The annealing temperature was 598C. In vitro methy-
lated DNA (IVD) was used as a positive control, and whole genome
amplified DNA (WGA) was used as a negative control. Each PCR re-
action (20 ml) was directly loaded onto 2% agarose gels, stained
with ethidium bromide, and visualized under UV illumination.
Genomic and Data Analysis
Expression analysis of tumors was performed using the Affy-
metrics U133 2.0 microarray (Affymetrix). Affymetrix CEL files
were imported into the Partek Genomics Suite (Partek). The
TCGA gene expression data (HT-HG-U133A) were accessed from
the TCGA data repositories (http://cancergenome.nih.gov; down-
loaded December 12, 2013). In total, 560 tumors were analyzed
for gene expression. We performed analysis of variance (ANOVA)
to identify genes that were differentially expressed between
MSKCC and TCGA LTSs and TCGA patients with survival ,1 year.
Differential expression was defined as a P value ,.05 with con-
cordant fold change of at least 1.25 fold which corresponds to
at least a 20% decrease and a 25% increase. Functional analysis
of this gene list was performed using DAVID bioinformatics re-
source and categories with adjusted P values (Benjamini) ,.05
considered significant. ANOVA was also performed to identify
genes that were differentially expressed between the TCGA LTSs
and the TCGA patients with survival ,1 year.
We performed unsupervised hierarchical clustering of the
MSKCC LTS and TCGA core tumors with survival information (n¼
177) using Kendall dissimilarity to classify the MSKCC LTSs into the
4 subtypes identified using the TCGA data.
For the validation set, expression datasets of 219 cases were
identified from the NCI Repository for Molecular Brain Neoplasia
Data (REMBRANDT; http://rembrandt.nci.nih.gov). We classified the
REMBRANDT dataset into LTSs .48 months (n¼ 16) and patients
with survival ,12 months (n¼ 73). We performed ANOVA to iden-
tify genes that were differentially expressed using the same criteria
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as in the TCGA dataset. Hypergeometric analysis was performed to
assess the significance of overlap of the 2 gene lists.
Results
Clinical Characteristics of Glioma Long-term Survivors
The clinical characteristics of the MSKCC LTSs are detailed in
Table 1. Patients had a mean age of 57 years (range, 32–70
years). All patients received radiation and chemotherapy, and
all but one patient (86%) had a gross total resection of the
tumor. The vast majority of patients (86%) had a KPS of 90%–
100% at presentation. Mean and median survival for the patients
was 75.5 months and 62.5 months, respectively (range, 50.6–
138.3 months). All patients were confirmed to have GBM with rep-
resentative hematoxylin-and-eosin stained slides pictured (Fig. 1).
Figure 2A shows the Kaplan-Meier plot of overall survival of the
LTS cohort.
Transcriptional Diversity of Tumors From Glioma
Long-term Survivors
In order to characterize the transcriptome of GBM tumors from
MSKCC LTSs, we obtained gene expression data using the Affy-
metrics U133 2.0 microarray. These data were imported along
with TCGA expression data (U133A). Both datasets contained
identical probes (n¼ 22 277). The data were normalized using
quantile normalization, and ANOVA was performed to correct
for batch effects. Mean values were obtained for duplicate tumors
and/or duplicate probes. Survival data for the MSKCC and TCGA
cohorts were obtained and used to classify patients as LTSs
(MSKCC, n¼ 7; TCGA, n¼ 26) and those with survival ,1 year
(TCGA, n¼ 209). Figure 2B shows the Kaplan-Meier plot for the
TCGA cohort used in the analysis (n¼ 533 with survival data).
Unsupervised hierarchical clustering was performed to classify
our samples into the subtypes identified in the TCGA data. In
order to do so, we used the well-validated 840 gene signature
described by Verhaak et al.11 and the core samples from the
TCGA dataset (n¼ 177 with survival data). Interestingly, instead
of uniformly classifying into a single subgroup, our patients clas-
sified into all 4 subgroups; 2 patients belonged to the proneural
subgroup, 2 to the neural subtype, 2 to the classical subtype,
and 1 to the mesenchymal subtype. Figure 3 shows unsupervised
hierarchical clustering of the MSKCC and TCGA samples. The tran-
scriptomal diversity of the MSKCC LTSs is further illustrated and
verified by comparing expression levels of genes representative
of each subtype (Supplementary Fig. S1).11,15
We then sought to determine which genes were differentially
expressed between the LTSs and patients with survival ,1 year.
In order to do so, we performed ANOVA between the LTSs
(MSKCC and TCGA) and the TCGA patients with survival ,1 year.
We did not restrict the analysis to the 840 gene signature but ra-
ther included all of the genes. Sixty genes were differentially
expressed between the 2 groups. None of these genes remained
significant after multiple test correction, which was likely due to
the relatively small numbers. A list of these genes can be found in
Table 2. We also performed this analysis using only the TCGA data,
examining differential gene expression between TCGA LTSs and
TCGA patients with survival ,1 year. When the MSKCC samples
were excluded from the analysis, all 60 genes from the initial ana-
lysis remained significant for differential expression. A list of
genes that were differentially expressed when the MSKCC sam-
ples were excluded from the analysis can be found in Supplemen-
tary Table S1. Among the 60 genes were CHI3L1, EMP3, IGFBP2,
IGFBP3, LGALS3, MAOB, PDPN, SERPING1, and TIMP1, which were
found (in an independent analysis) to be associated with survival
with decreased expression correlated with longer survival.16 Also
among this list were 7 genes (CBR1, CHI3L1, F3, FMOD, LGALS3,
PDPN, and RBP1) that are among the top 50 most differentially
hypermethylated and downregulated genes in proneural
G-CIMP-positive tumors.8,9 Gene ontology pathway analysis was
performed using the DAVID bioinformatics resource. The LTSs
were found to have downregulation of genes involved in response
to inflammation including response to wounding, acute inflam-
matory response, and humoral inflammatory response (Supple-
mentary Table S2).
In the updated TCGA analysis,13 the LTSs (.3 years) were ana-
lyzed and found to have somewhat fewer amplifications of CDK4
and EGFR and fewer deletions of CDKN2A. Though we were unable
to assess copy number, we did look at expression level for these
genes and found no statistical difference between the MSKCC LTSs
and the TCGA patients with survival ,1 year (See Supplementary
Fig. S2A and B).
Molecular Genetic Analysis
After determining that there was transcriptomal diversity among
the LTSs from our institution, we sought to determine whether
all of our LTSs were IDH1 or IDH2 mutant and/or positive for
hypermethylation of the MGMT promoter, 2 known indicators of
Table 1. Clinical information for Memorial Sloan Kettering Cancer Center
long-term survivors
Variable Patients (%)




Radiation therapy, any 7 (100)
6000–6290 cGy 4 (57)
Gamma knife, 1100 cGy 1 (14)
Unknown dose 2 (29)
Chemotherapy 7 (100)
Temodar 6 (86)











Abbreviation: KPS, Karnofsky performance status.
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good prognosis. On targeted sequencing of R132 for IDH1 and
R172 for IDH2, none of the MSKCC LTSs were found to possess
mutant IDH1 or 2.
To determine MGMT methylation status, methylation-specific
PCR was used and revealed that 5 of the 7 MSKCC LTSs (71%)
showed methylation positivity, while 2 were unmethylated (as
shown in Figure 4).
We then reviewed the association of IDH1 and LTS in the TCGA
dataset. The mutation status of IDH1 was available in 22 of the
LTSs in the TCGA dataset. Of these 22 patients, 6 (27%) were mu-
tant for IDH1. Of the remaining 295 patients with IDH1 mutation
status who were not LTSs (living patients excluded since survival
status not yet determined), 12 were mutant for IDH1 (4%).
Table 3 summarizes the molecular features of the MSKCC and
TCGA LTS patients.
Validation of Long-term Survivor Gene Expression
Patterns Using the REMBRANDT Cohort
In order to further validate the findings found in the TCGA and
MSKCC cohorts, we sought to establish the reproducibility of our
observations by using the independent REMBRANDT dataset.
After accounting for duplicate samples and duplicate probes,
we were left with gene expression data from 219 patients, 186
of whom had survival data. Among these 186 patients, there
were 16 LTSs and 73 with survival ,1 year. We performed
ANOVA to compare genes that were differentially expressed
between the LTSs and those patients with survival ,1 year.
Twenty-five of the 60 genes found to be significant in the TCGA
and MSKCC datasets were also significant in the REMBRANDT
data, many of which were downregulated in the LTS tumors.
These genes are denoted by an asterisk in Table 2. These genes
include CHI3L1, EFEMP1, EMP3, NAMPT, C1S, and PDGFA. We per-
formed a hypergeometric analysis of the genes that overlapped
between the TCGA and MSKCC data and the REMBRANDT data.
The P value obtained was 1.83×10– 19, demonstrating statistical-
ly significant overlap. There was no difference in expression levels
of EGFR and CDKN2A between the MSKCC and REMBRANDT LTSs
and the REMBRANDT patients with survival ,1 year (Supplemen-
tary Fig. S2C and D).
Finally, we sought to classify the REMBRANDT dataset into the
TCGA transcriptional subtypes in order to determine if the LTSs in
the validation cohort were also diverse with regard to subtype. In
order to do so, we performed unsupervised hierarchical clustering
Fig. 1. Representative slides from the tumors of MSKCC long-term survivors. Staining was performed with hematoxylin and eosin. Scale bars represent
200mM. (A) Sample LTS 6 with arrow indicating area of necrosis. (B) Sample LTS 3 with arrows indicating areas of endothelial proliferation.
Fig. 2. Kaplan–Meier plot of overall survival of (A) the MSKCC long-term survivors and (B) TCGA dataset used for analysis. Black line indicates 48-month
cutoff for long-term survivors used in this series.
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using the 840 gene signature identified by Verhaak et al.11 of the
TCGA core samples and the REMBRANDT LTSs (Fig. 5). As with the
LTSs in the MSKCC cohort, the LTSs in the REMBRANDT dataset
belonged to all 4 subtypes, with 44% classified as proneural
and the remainder divided among classical, mesenchymal, and
neural subtypes. The distribution of the LTSs from all 3 datasets
is pictured in Figure 6. We also performed unsupervised hierarch-
ical clustering on the REMBRANDT samples alone (Supplementary
Fig. S3) and found that the LTSs in the REMBRANDT dataset were
similarly distributed among all 4 subtypes.
Discussion
In this study, we describe the transcriptomal and molecular fea-
tures of patients with GBM with survival.4 years. One strength of
this study is the long mean and median survival of our cohort
(75.5 months and 62.5 months, respectively; .3 standard
deviations above the mean survival for all-comers), highlighting
the fact that our cohort consists of extreme outliers with long-
term survival among patients with GBM. Our data add to an
important body of literature examining genomic predictors of
outcome in GBM.
In identifying patients with survival .4 years, we selected the
extreme outliers with this deadly disease. Surprisingly, these LTSs
fell within all 4 TCGA transcriptomal subgroups, and none har-
bored an IDH mutation. Since IDH-mutant/CIMP-positive pro-
neural tumors have been linked to improved survival (at least in
the short term), it was reasonable to expect that the vast majority
of the extreme LTSs would be of the proneural subtype or harbor
IDH mutation.7 – 9,17 – 19 Using 3 independent cohorts, our study
shows that long-term survival can be achieved in patients with
nonproneural tumors and no IDH mutations. Nevertheless, in 2
of the 3 cohorts (TCGA and REMBRANDT), 50% of the LTSs
were proneural, and in the TCGA cohort, 27% of the LTSs harbored
IDH mutations. Previous studies have also shown higher
Fig. 3. Classification of GBM long-term survivors (LTSs) into TCGA subgroups. Unsupervised hierarchical clustering was used to classify the 7 MSKCC LTS
patients and 15 TCGA LTS patients into the TCGA subgroups. One hundred sixty-one TCGA core samples and 7 MSKCC samples are shown in the heat
map above. Color scale indicates normalized relative expression. TCGA subgroup identity for each cluster is noted and color coded along the Y-axis.
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Table 2. Genes differentially expressed between MSKCC and TCGA long-term survivors versus TCGA patients with survival less than 1 year
Gene Symbol P value Percent
Change
Increase or Decrease
in LTS vs. patients
with survival ,1 year
Description
EFEMP2* 0.000091 31.31 Decrease EGF containing fibulin-like extracellular matrix protein 2
CHI3L1* 0.004373 44.95 Decrease chitinase 3-like 1 (cartilage glycoprotein-39)
MSN 0.004389 25.28 Decrease Moesin
PDPN* 0.004496 26.12 Decrease Podoplanin
LOC390940* 0.004600 20.55 Decrease Protein LOC390940
IGFBP2* 0.004785 39.00 Decrease Insulin-like growth factor binding protein 2
SPP1* 0.004798 35.29 Decrease Secreted phosphoprotein 1
TIMP1 0.004898 37.38 Decrease Tissue inhibitor of metalloproteinase 1
FKBP9* 0.007392 23.47 Decrease FK506 binding protein 9, 63 kDa
C1R* 0.007482 31.76 Decrease Complement C1r subcomponent
WWTR1 0.007926 20.50 Decrease WW domain containing transcription regulator 1
FMOD* 0.007932 26.67 Decrease fibromodulin
DUSP6 0.009469 23.63 Decrease Dual specificity protein phosphatase 6
CLEC5A* 0.009478 20.59 Decrease C-type lectin domain family 5 member A
CHST2 0.009603 23.15 Decrease Carbohydrate sulfotransferase 2
CHL1 0.009900 34.00 Decrease cell adhesion molecule L1-like protein
EMP3* 0.010202 32.50 Decrease epithelial membrane protein 3
AEBP1* 0.012936 31.90 Decrease Adipocyte enhancer-binding protein 1
HIST3H2A 0.014230 32.37 Increase Histone H2A type 3
DIRAS3* 0.014387 24.36 Decrease GTP-binding protein Di-Ras3
SERPING1* 0.015011 28.54 Decrease Serin peptidase inhibitor, clade G, member 1
CBR1* 0.015149 20.98 Decrease Carbonyl reductase [NADPH] 1
FABP7 0.015658 32.75 Decrease Fatty acid-binding protein, brain
FZD7* 0.016326 22.39 Decrease frizzled family receptor 7
RBP1 0.016362 35.50 Decrease Retinol-binding protein 1
SCG5* 0.017010 31.36 Decrease Secretogranin V
F3 0.017753 25.51 Decrease coagulation factor III (thromboplastin, tissue factor)
C1S* 0.017854 31.36 Decrease Complement C1s subcomponent
FAM46A 0.018064 21.56 Decrease family with sequence similarity 46, member A
PLSCR1 0.018198 21.25 Decrease Phospholipid scramblase 1
TMEM158* 0.019466 30.96 Decrease Transmembrane protein 158
GBP1 0.023537 27.14 Decrease Interferon-induced guanylate-binding protein 1
CD24 0.024976 48.86 Increase CD24 molecule
DYNLT3 0.026435 20.29 Decrease Dynein, light chain, Tctex-type 3
NAMPT* 0.028738 29.91 Decrease Nicotinamide phosphoribosyltransferase
LGALS3* 0.028989 31.57 Decrease lectin, galactoside-binding, soluble, 3
CD14 0.030171 28.67 Decrease CD14 molecule
PDGFA* 0.032116 20.34 Decrease Platelet-derived growth factor subunit A
ADM 0.033162 32.99 Decrease adrenomedullin
SEC61G* 0.033389 33.20 Decrease Protein transport protein Sec61 subunit gamma
SERPINA3 0.034414 37.00 Decrease Serpin peptidase inhibitor, clade A, member 3
A2M 0.034520 24.66 Decrease Alpha-2-macroglobulin
PMP22 0.035318 23.11 Decrease Peripheral myelin protein 22
DPYD 0.037046 24.90 Decrease Dihydropyrimidine dehydrogenase [NADP(+)]
CSRP1 0.037825 22.15 Decrease Cysteine and glycine-rich protein 1
IGFBP3* 0.038283 30.79 Decrease Insulin-like growth factor binding protein 3
MAOB 0.038425 32.38 Decrease Monoamine oxidase B
MT1M 0.039683 30.55 Decrease Metallothionein 1M
TMEM176B 0.039863 25.14 Decrease Transmembrane protein 176B
AKAP12 0.041885 25.59 Decrease A-kinase anchor protein 12
TRIM22 0.042183 22.67 Decrease E3 ubiquitin-protein ligase TRIM22
Continued
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incidence of IDH1 mutations in LTSs as compared with short-term
survivors (STS)20 or non-LTSs.21 Therefore, it appears that these
features are associated with survival out to 4 years and beyond.
The discrepancy between our data and prior series may reflect a
selection bias or a difference in the biological distribution of the
MSKCC patients. Nevertheless, this study demonstrates that
GBM survivorship out to 4 years or longer can occur in patients
of all subgroups and in patients without IDH mutations.
The high rate of MGMT promoter hypermethylation in our
group of LTS is consistent with prior data showing frequent hyper-
methylation of MGMT in LTSs.20,22 It is also consistent with data
that LTSs with wild-type IDH1/2 have a higher rate of MGMT
promoter methylation compared with STS with wild-type
IDH 12.
21 Our data indicate that MGMT methylation remains a
powerful predictor of long-term survivorship to beyond 4 years.
In the most recent update of the TCGA data,13 Brennan et al.,
examined the LTSs (.3 year survival). They reported no specific
genomic alteration that was significantly over- or underrepre-
sented in this cohort, although they noted fewer amplifications
of CDK4 and EGFR and fewer deletions of CDKN2A in the LTSs.
Using expression as a proxy for copy number, we did not observe
differences in expression of these specific genes in our data. How-
ever, we did find a list of genes that were differentially expressed
between the LTSs and those with survival ,1 year, which was
found to have significant overlap with a gene list generated
using the independent REMBRANDT dataset. Furthermore, there
was overlap between our gene signature and previous signatures
identified by Colman et al.16 and Kim et al.,23 as being prognostic
of survival, although we note that some of this overlap might
have been due to use of the same TCGA data in the latter
study. Interestingly, some of the genes we identified as being
downregulated in our signature are also known to be among
the most differentially hypermethylated and downregulated
genes in proneural G-CIMP positive tumors,8 which further
implicate these genes in survivorship. Our definition of LTSs of
.4 years and our comparison group as having survival ,1 year
was more restrictive than the definition used in other studies16,23
(survival . vs. ,2 years). Thus, we hypothesize that the gene
expression changes observed in our study better predict very
long survival for GBM patients.
Though our LTSs did not classify into a single subgroup, many
of the genes that were differentially downregulated in the LTS
tumors in this study (eg, CHI3L1 (YKL40), EFEMP2, EMP3,
LGALS3, PDPN, and TIMP1) are associated with mesenchymal tis-
sues and/or the extracellular matrix (ie, the mesenchymal sub-
group).11 – 13 The MSKCC and TCGA LTSs showed lower levels of
expression of these genes as compared with the TCGA STS. This
Table 3. Summary of molecular features of Memorial Sloan Kettering
Cancer Center long-term survivors
Molecular feature MSKCC LTSs % TCGA LTSs (%)
Transcriptional subgroup n¼ 7 n¼ 27
Proneural 2 (29) 13 (48)
Classical 2 (29) 4 (15)
Mesenchymal 1 (14) 7 (26)
Neural 2 (29) 3 (11)
MGMT methylated 5 (71) 10 (67) (n¼ 15 with
available data)
IDH 1/2 mutated 0 (0) 6 (27) (n¼ 22 with
available data)
Abbreviations: LTSs, long-term survivors; MSKCC, Memorial Sloan Kettering
Cancer Center; TCGA, The Cancer Genome Atlas.
Fig. 4. Methylation status of the MGMT promoter in the MSKCC long-term
survivors. A methylation-specific PCR assay was used, with in vitro
methylated DNA (IVD) used as a positive control, whole genome
amplified DNA (WGA) used as a negative control for methylation, and
water as a negative PCR control. “U” denotes the presence of
unmethylated alleles and “M” the presence of methylated alleles. Five
glioblastoma samples (201, 202, 205, 206, and 204) show methylation,
and 2 samples (207, 203) are unmethylated.
Table 2. Continued
Gene Symbol P value Percent
Change
Increase or Decrease
in LTS vs. patients
with survival ,1 year
Description
BST2* 0.042421 22.07 Decrease Bone marrow stromal antigen 2
BASP1 0.042542 39.41 Increase Brain acid soluble protein 1
FCGR2B 0.043519 20.62 Decrease Low affinity immunoglobulin gamma Fc region receptor II-b
CD99 0.044209 21.97 Decrease CD99 molecule
TNFAIP6 0.044390 23.09 Decrease Tumor necrosis factor-inducible gene 6 protein
TMEM176A 0.047687 23.46 Decrease Transmembrane protein 176A
POSTN 0.047970 27.83 Decrease Periostin
SLC1A3 0.048246 29.60 Decrease Excitatory amino acid transporter 1
CCL2 0.048957 32.36 Decrease C-C motif chemokine 2
*also significant in REMBRANDT data set.
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Fig. 5. Classification of REMBRANDT long-term survivors (LTSs) and TCGA samples into TCGA subgroups. Unsupervised hierarchical clustering of TCGA
samples and REMBRANDT LTSs. Color scale indicates normalized relative expression.
Fig. 6. Distribution of long-term survivors from 3 datasets among the The Cancer Genome Atlas transcriptional subtypes.
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finding is consistent with previous observations attributing a
poorer prognosis with higher expression of mesenchymal-
angiogenic associated-genes.12,16,23 Further analysis of the dif-
ferentially expressed genes revealed a downregulation of genes
involved in response to inflammation such as A2M, CCL2, PDPN,
CHST2, SERPING1, C1R, C1S, F3, SERPINA3, and SPP1. Eighteen of
the 60 differentially expressed genes (30%) were involved in
response to wounding. Other significant pathways included
defense response, acute inflammatory response, and regulation
of response to external stimuli. This downregulation of inflam-
matory and immune markers was consistent with a recent
14-gene prognostic signature that found active inflammatory re-
sponse pathway in a high-risk group of GBM patients.24 The asso-
ciation of a reduced inflammatory response with LTSs may have
been due to reduction in an active inflammatory environment
leading to decreased tumor growth and progression.25
In conclusion, we have demonstrated that extreme LTSs of
GBM do not represent a single molecular subtype but are tran-
scriptomally diverse. Furthermore, MGMT methylation was com-
mon in our cohort and continues to be prognostic for very
long-term survival. IDH1 and IDH2 mutations were not present
in any of the MSKCC LTSs examined in this study and may not
be required to achieve survivorship to beyond 4 years. These
data have significant implications for understanding the determi-
nants of survival in GBM patients.
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